New advances in the discovery of thrombin and factor Xa inhibitors.
The search for the ideal anticoagulant has spanned decades and has resulted in several strategies including the clinical use of heparin, low molecular weight heparins, and the vitamin K antagonist warfarin. Over the past five years, many groups have reported preclinical results with direct-acting thrombin inhibitors and several of these are now moving into clinical trials. In addition, many groups have disclosed the discovery of potent, orally bioavailable factor Xa inhibitors. Several of these compounds are now in early clinical trials and the results are forthcoming.
Vacca
J P
JP
Merck Research Laboratories, West Point, PA 18969, USA. joe_vacca@merck.com
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use*; D000991:Antithrombins / Q000494:pharmacology* / Q000627:therapeutic use; D065427:Factor Xa Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D015394:Molecular Structure; D051381:Rats; D015912:Thrombolytic Therapy
D000925:Anticoagulants; D000991:Antithrombins; D065427:Factor Xa Inhibitors